BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23280926)

  • 1. Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis.
    Minovski N; Perdih A; Novic M; Solmajer T
    J Comput Chem; 2013 Apr; 34(9):790-801. PubMed ID: 23280926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling of Mycobacterium tuberculosis DNA gyrase and its molecular docking study with gatifloxacin inhibitors.
    da Cunha EE; Barbosa EF; Oliveira AA; Ramalho TC
    J Biomol Struct Dyn; 2010 Apr; 27(5):619-25. PubMed ID: 20085379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
    Sriram D; Aubry A; Yogeeswari P; Fisher LM
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MM2QM tool for combining docking, molecular dynamics, molecular mechanics, and quantum mechanics.
    Nowosielski M; Hoffmann M; Kuron A; Korycka-Machala M; Dziadek J
    J Comput Chem; 2013 Apr; 34(9):750-6. PubMed ID: 23233437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv.
    Agrawal H; Kumar A; Bal NC; Siddiqi MI; Arora A
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3053-8. PubMed ID: 17418569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
    Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
    J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
    Dinakaran M; Senthilkumar P; Yogeeswari P; China A; Nagaraja V; Sriram D
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1229-36. PubMed ID: 18068979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
    Tran AT; West NP; Britton WJ; Payne RJ
    ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of novel quinoline-aminopiperidine derivatives as
    Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
    J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
    Maharaj Y; Soliman ME
    Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
    Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
    J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase.
    Petersen GO; Saxena S; Renuka J; Soni V; Yogeeswari P; Santos DS; Bizarro CV; Sriram D
    J Mol Graph Model; 2015 Jul; 60():124-31. PubMed ID: 26043661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemistry. Protein that mimics DNA helps tuberculosis bacteria resist antibiotics.
    Ferber D
    Science; 2005 Jun; 308(5727):1393. PubMed ID: 15933168
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
    Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues.
    Jeankumar VU; Renuka J; Kotagiri S; Saxena S; Kakan SS; Sridevi JP; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
    ChemMedChem; 2014 Aug; 9(8):1850-9. PubMed ID: 24962352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis.
    Fakhar Z; Naiker S; Alves CN; Govender T; Maguire GE; Lameira J; Lamichhane G; Kruger HG; Honarparvar B
    J Biomol Struct Dyn; 2016 Nov; 34(11):2399-417. PubMed ID: 26612108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel inhibitors against Mycobacterium tuberculosis L-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening.
    Saxena S; Devi PB; Soni V; Yogeeswari P; Sriram D
    J Mol Graph Model; 2014 Feb; 47():37-43. PubMed ID: 24316937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tubercular drug designing by structure based screening of combinatorial libraries.
    Ghosh P; Bagchi MC
    J Mol Model; 2011 Jul; 17(7):1607-20. PubMed ID: 20953648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.